The proposed offering could raise up to $18.75 million at the top end of the price range. While the company has not yet disclosed its intended ticker symbol or exchange, the filing signals an aggressive push to capitalize on its development-stage pipeline.
In section Market Quotes
EIR Biopharma Files for IPO to Fund Eye Disease Pipeline
EIR Biopharma, an early-stage biotechnology firm specializing in ophthalmology, filed for an initial public offering on Tuesday to advance its lead therapeutic candidate. The company plans to sell 3.75 million shares of common stock at a price range of $4 to $5 per share, according to a filing with the Securities and Exchange Commission.
Capital Strategy for EIR-1003
Proceeds from the IPO are earmarked primarily for the preclinical and clinical development of EIR-1003, the company's flagship therapeutic candidate. Beyond direct drug development, the firm plans to allocate the new capital toward several operational areas:
- Ongoing research and development activities
- Working capital requirements
- General corporate purposes
Comments (0)
No comments yet. Be the first!